Clinical Trials Browser

Phase 2/3 × NETWORK × Docetaxel × Clear all

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01924819 2025-03-04

TOPGEAR

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT02766335 2023-05-25

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Phase 2/3 Completed

116 enrolled 23 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2/3 Completed

43 enrolled 15 charts

FGFR1 Gene Amplification

NCT01603420 2016-03-14

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

Phase 2/3 Terminated

2 enrolled 8 charts

Neoplasms, Prostatic Neoplasms